Chief Executive Officer
John P. McLaughlin has served as our Chief Executive Officer since December 2008, when the Company spun-off Facet Biotech Corporation (Facet Biotech). From December 2008 until September 2017, Mr. McLaughlin served the Company as both President and Chief Executive Officer.
Mr. McLaughlin was elected a director of the Company in October 2008 and from November 6, 2008 until the spin-off on December 18, 2008, he served as a Senior Advisor to the Company. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr. McLaughlin served as counsel to various subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws. Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc. He also co-founded and served as a director of Peak Surgical, Inc., a privately-held medical device company subsequently purchased by Medtronic, Inc. He also served as a director of AxoGen, Inc., Adverum Biotechnologies, Inc. and Seattle Genetics, publicly-traded biopharmaceutical companies. He received a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America. Mr. McLaughlin possesses a strong understanding of the biotechnology industry and has experience in development, regulation and commercialization of drugs, corporate licensing and litigation that the Company values. In addition, Mr. McLaughlin provides strategic guidance to our management team and the Board.
Dominique Monnet, our President, joined the Company in September 2017. Before joining PDL, Mr. Monnet served as senior vice president and chief marketing officer of Alexion Pharmaceuticals in 2014 to 2015 where he was responsible for commercial operations in the U.S. and Latin America and oversaw new products and global business operations functions.
Vice President and Chief Financial Officer
Peter Garcia, our Vice President and Chief Financial Officer, joined the Company in May, 2013. Before joining PDL, Mr. Garcia served as CFO of BioTime, Inc., which he joined in 2011. Between the years of 1996 and 2011, Mr. Garcia was CFO of six biotech and high-tech companies, including Marina Biotech, Nanosys, Nuvelo, Novacept, IntraBiotics Pharmaceuticals and Dendreon Corporation.
Vice President and General Counsel
Christopher Stone, our Vice President, General Counsel and Secretary, joined the Company in February 2009. He brings more than 27 years of legal experience to the role. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection, research collaborations and licensing.
Vice President, Business Development
Danny Hart, our Vice President, Business Development, focuses on the Company’s investment activity by identifying, evaluating, structuring and completing the Company’s alternative, non-dilutive financing investments (structured debt, synthetic royalty, royalty monetization) for late-stage pharmaceutical, device and diagnostic companies.
Vice President, Finance, and Chief Accounting Officer
Steffen Pietzke, currently our Vice President, Finance, and Chief Accounting Officer, joined the company in June, 2015. Prior to PDL, Mr. Pietzke was a Senior Manager with Ernst & Young LLP (EY) since 2013. He provided audit and related financial services to both public and private companies in the U.S., Europe and China.
Deputy General Counsel
Nathan Kryszak, our Deputy General Counsel and Assistant Secretary joined the Company in August 2014 as Senior Counsel. Since joining the Company, Mr. Kryszak was appointed Assistant Secretary in September 2014 and promoted to Deputy General Counsel effective January 2017.
Mr. Edick brought over 35 years of experience in the life sciences industry to PDL when he was elected to the board in September of 2015. Mr. Edick is currently the President and CEO of Xeris Pharmaceuticals, Inc. Prior to Xeris, he was managing partner of 3G Advisors, LLC.
David W. Gryska was elected a director in March 2014. Mr. Gryska is currently serving as Executive Vice President and Chief Financial Officer for Incyte Corporation. Prior to Incyte Mr. Gryska served as Chief Operating Officer and a director of Myrexis, Inc., a biotechnology company, from May 2012 to December 2012.
Jody S. Lindell was elected a director of the Company in March 2009. Ms. Lindell is President and Chief Executive Officer of S.G. Management, Inc., an asset management company she has headed since 2000. Prior to that, Ms. Lindell was a partner with KPMG LLP where she served as Partner-In-Charge of the Industrial Markets and Healthcare
Chief Executive Officer
John P. McLaughlin was elected a director of the Company in October 2008 and has served as Chief Executive Officer since December 2008, after the Company spun-off Facet Biotech Corporation (Facet Biotech). From December 2008 until September 2017, Mr. McLaughlin served the Company as both President and Chief Executive Officer.
Dr. Saks was first appointed a director of the Company in September of 2015. He is a board certified oncologist who most recently served as chief development officer for Auspex Pharmaceuticals, Inc., a position he held from 2013 until it was acquired by Teva Pharmaceuticals Industries, Ltd. in May 2015.
Paul W. Sandman was elected a director of the Company in October 2008. Mr. Sandman served at Boston Scientific Corporation in various management positions from May 1993 to February 2008, most recently as its Executive Vice President, Secretary and General Counsel. From 1984 to April 1993, he served at Wang Laboratories, Inc., most recently as Senior Vice President, General Counsel and Secretary.
Harold E. Selick, Ph.D., was elected a director in August 2009. Currently Dr. Selick is serving as Vice Chancellor of Innovation and Partnerships at the University of California, San Francisco. Prior to that, Dr. Selick has served as Chief Executive Officer and a director of Threshold Pharmaceuticals, Inc., a publicly-traded biotechnology company. From June 2002 until April 2017, where he still serves as Chairman of the Board of Directors.
As co-inventor of technology that underlies the Queen et al. patents, Dr. Selick provides the Board with a scientific perspective and a unique appreciation of the Company’s assets. Dr. Selick also provides the Board with operational experience derived from his role as a chief executive officer of a publicly-traded biotechnology company.